Teva Pharmaceuticals Earmarks $520M To End FCPA Claims
Teva Pharmaceuticals has earmarked $520 million for possible settlements with the U.S. Department of Justice and the U.S. Securities and Exchange Commission regarding alleged violations of the Foreign Corrupt Practices Act...To view the full article, register now.
Already a subscriber? Click here to view full article